Heron Therapeutics (HRTX) Change in Account Payables (2010 - 2026)
Heron Therapeutics (HRTX) reported Change in Account Payables of -$24000.0 for Q1 2026, down 103.85% on a YoY basis from $624000.0 in Q1 2025, and up 99.21% quarter-over-quarter from -$3.0 million in Q4 2025.
Heron Therapeutics (HRTX) Change in Account Payables (2010 - 2026) Analysis & Trends
Heron Therapeutics has reported Change in Account Payables for 17 years, with the latest figure at -$24000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 103.85% year-over-year to -$24000.0; the trailing twelve-month figure through Mar 2026 stood at -$3.4 million (down 129.25% YoY), and the FY2025 full-year result was -$2.7 million, down 132.06% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$24000.0, up from -$3.0 million in the prior quarter.
- The five-year high for Change in Account Payables was $9.4 million in Q2 2024, with the low at -$7.3 million in Q3 2022.
- Historically, Change in Account Payables has averaged $303941.2 across 5 years, with a median of -$24000.0 in 2026.
- The largest YoY upside for Change in Account Payables was 545.4% in 2024 against a maximum downside of 386.07% in 2024.
- Heron Therapeutics' Change in Account Payables stood at -$3.3 million in 2022, then surged by 141.54% to $1.4 million in 2023, then climbed by 10.22% to $1.5 million in 2024, then slumped by 298.75% to -$3.0 million in 2025, then jumped by 99.21% to -$24000.0 in 2026.
- The last three Change in Account Payables figures came in at -$24000.0 (Q1 2026), -$3.0 million (Q4 2025), and -$20000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -9.42 Mn |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn | -24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24,000.00 |
| Mar 31, 2026 | -24,000.00 |
| Dec 31, 2025 | -3.02 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -20,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | -296,000.00 |
| Jun 30, 2025 | -296,000.00 |
| Mar 31, 2025 | 624,000.00 |
| Mar 31, 2025 | 624,000.00 |
| Dec 31, 2024 | 1.52 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | -38,000.00 |
| Sep 30, 2024 | -38,000.00 |
| Jun 30, 2024 | 9.39 Mn |
| Jun 30, 2024 | 9.39 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Dec 31, 2023 | 1.38 Mn |